Barclays raises target for Qiagen stock from USD 40.00 to USD 55.00

Published on 10/07/2026 at 10:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock costs EUR 40.78 on October 7, 2026 versus EUR 40.58, plus 0.49 percent. Second-quarter sales reached USD 535.00 million.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen (ISIN NL0015002SN0) stock was trading at EUR 40.78 at Lang & Schwarz on October 7, 2026 at 10:02 a.m. CEST, up 0.49 percent from the EUR 40.58 prior close. The latest market catalyst is Barclays' upgrade to Overweight and its target increase from USD 40.00 to USD 55.00 on October 6, 2026, reported by GuruFocus.

Barclays resets the valuation bar

Barclays analyst Luke Sergott moved Qiagen from Equal-Weight to Overweight and lifted the target by USD 15.00, a 37.50 percent increase from the previous USD 40.00 target, according to GuruFocus on October 6, 2026. The new target is 20.29 percent above the Lang & Schwarz euro price only as a directional market reference, not a same-currency valuation comparison.

The upgrade arrives against a mixed research backdrop. Zacks assigned Qiagen a Rank 3 Hold in its September 4, 2026 review, while its report said fresh estimates had been trending downward.

Second-quarter growth stayed selective

Qiagen reported USD 535.00 million of net sales in the second quarter of 2026, up 0.30 percent year over year and 1.40 percent above consensus, according to Zacks. Adjusted earnings per share reached USD 0.62, up 3.30 percent year over year and 3.30 percent above consensus, while GAAP earnings per share were USD 0.50.

Performance varied sharply by business line. Sample technologies revenue rose 9.00 percent at constant exchange rates to USD 182.00 million, while PCR and nucleic acid amplification revenue fell 8.00 percent at constant exchange rates to USD 74.00 million. The contrast makes product mix and the rollout of newer instruments central to the second-half outlook.

Guidance points to a stronger second half

In its second-quarter 2026 earnings call, Yahoo Finance reported that management reaffirmed adjusted earnings per share of at least USD 2.43 for fiscal 2026. Management also expects second-half sales growth of 3.00-4.00 percent at constant exchange rates, compared with a 1.00 percent decline in the first half.

The main counterweight is execution. QIAstat-Dx revenue fell 7.00 percent at constant exchange rates in the second quarter, and the transcript said U.S. funding remained below the first-half 2025 level despite sequential improvement. That leaves Barclays' more constructive valuation dependent on product launches and a recovery in demand.

Qiagen stock holds near EUR 41.00

Qiagen stock was trading at EUR 40.78 at Lang & Schwarz on October 7, 2026 at 10:02 a.m. CEST, plus 0.49 percent versus the prior close of EUR 40.58. The company is listed on the NYSE as QGEN and on Frankfurt Prime Standard as QIA, while its business centers on molecular diagnostics and life sciences research. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.